Erasca, Inc. (NASDAQ:ERAS)
| Market Cap | 5.41B+576.0% |
| Revenue (ttm) | 0 |
| Net Income | -287.22M-123.9% |
| EPS | -0.95-111.1% |
| Shares Out | 349.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,984,545 |
| Open | 15.43 |
| Previous Close | 15.61 |
| Day's Range | 15.00 - 15.66 |
| 52-Week Range | 2.21 - 24.28 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 21.43(+38.44%) |
| Earnings Date | Nov 11, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ERAS
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating ERAS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 11, 2026Earnings report
$ERAS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ERAS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ERAS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ERAS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ERAS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ERAS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ERAS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $148.64M |
| XBIState Street SPDR S&P Biotech ETF | $134.59M |
| IWMiShares Russell 2000 ETF | $90.02M |
| VBVanguard Morningstar Small-Cap ETF | $52.00M |
| VXFVanguard Extended Market ETF | $47.93M |
| VBRVanguard Morningstar Small-Cap Value ETF | $33.80M |
Estimated from each fund’s disclosed top holdings × AUM
ERAS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ERAS’s recent data — informational, not investment advice